ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2014
Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Evaluating Orally Administered Meloxicam-Loaded Polymeric Nanocapsules in Female Dogs: A Population Pharmacokinetic Modeling Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Effectiveness, Safety, and Pharmacokinetics of Meloxicam Formulations in African-clawed Frogs, Xenopus laevis.Comparative medicine · 2024Article
- The cost of research: Lasting effects of capture, surgery and muscle biopsy on brown bear (Animal welfare (South Mimms, England) · 2023Article
- Challenges with Assessing and Treating Pain in Research Primates: A Focused Survey and Literature Review.Animals : an open access journal from MDPI · 2022Review
- Association of Primate Veterinarians Guidelines for Wound Management of Nonhuman Primates.Journal of the American Association for Laboratory Animal Science : JAALAS · 2022Article
- Current Topics in Marmoset Anesthesia and Analgesia.ILAR journal · 2020Review
- Injection-site Reactions to Sustained-release Meloxicam in Sprague-Dawley Rats.Journal of the American Association for Laboratory Animal Science : JAALAS · 2020Article
- Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs.Journal of the American Association for Laboratory Animal Science : JAALAS · 2020Article
- Concentration-dependent Toxicity after Subcutaneous Administration of Meloxicam to C57BL/6N Mice (Journal of the American Association for Laboratory Animal Science : JAALAS · 2019Article
- Preliminary Evaluation of Sustained-release Compared with Conventional Formulations of Meloxicam in Sheep (Journal of the American Association for Laboratory Animal Science : JAALAS · 2019Article
- Plasma Concentration of Meloxicam in Pediatric Rats.Journal of the American Association for Laboratory Animal Science : JAALAS · 2017Article
- Evaluation of carboplatin sustained-release delivery system in dogs with cancer.Veterinary medicine and science · 2016Article
- Postoperative Analgesia Due to Sustained-Release Buprenorphine, Sustained-Release Meloxicam, and Carprofen Gel in a Model of Incisional Pain in Rats (Rattus norvegicus).Journal of the American Association for Laboratory Animal Science : JAALAS · 2016Article
- Pharmacokinetics of 2 Formulations of Transdermal Fentanyl in Cynomolgus Macaques (Macaca fascicularis).Journal of the American Association for Laboratory Animal Science : JAALAS · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Meloxicam is a commonly used COX2-preferential NSAID in both human and veterinary patients. Minimal information has been published regarding appropriate dosing in nonhuman primates. Here we investigated the pharmacokinetic parameters of 3 formulations of meloxicam in cynomolgus macaques. A single dose of meloxicam SR, an extended-release formulation purported to provide therapeutic levels for as long as 72 h, was compared with the intramuscular and oral formulations dosed for 3 consecutive days and as a single dose. The oral formulation, both over 3 d and as a single dose, yielded lower plasma levels and a shorter duration than did intramuscular and sustained-release subcutaneous formulations. The intramuscular formulation, both over 3 d and as a single dose, provided lower plasma levels and a shorter duration than did a sustained-release subcutaneous formulation. The sustained-release formulations generated the highest plasma concentrations for the longest periods of time. None of the formulations caused significant effects on kidney or liver function. Our results indicate that the sustained-release formulation of meloxicam can achieve an adequate steady-state plasma concentration for 2 to 3 d in nonhuman primates. The standard intramuscular formulation provides adequate plasma concentrations for 12 to 24 h, with waxing and waning levels associated with daily dosing. The oral formulation has limited utility in nonhuman primates because of low circulating levels of drug.
Indexed as
Identifiers
25255073PMC4181692W2399902752What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.